Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Novavax COVID Vaccine to Be Adapted to JN.1 Strain: Takeda
Takeda Pharmaceutical said on June 6 that a two-dose vial version of its COVID-19 vaccine Nuvaxovid, licensed by Novavax, will be supplied as a shot adapted to the JN.1 strain of the novel coronavirus in Japan. Takeda filed the two-dose…
To read the full story
Related Article
- Japan Panel OKs 5 COVID Vaccines for NIP Use from October
September 20, 2024
- JN.1-Targeting Nuvaxovid Approved in Japan: Takeda
September 6, 2024
- Japan Expects COVID Vaccine Supply of 32 Million Doses from 5 Makers in 2024-25
September 3, 2024
- Japan Panel OKs BMS ROS1 Inhibitor, Janssen Bispecific, JN.1-Targeted Nuvaxovid
September 2, 2024
- BMS’ ROS1 Inhibitor, Janssen’s Bispecific Up for Review on Aug. 30
August 20, 2024
- Japan Selects JN.1 for COVID-19 Vaccine Formula in 2024-2025 Season
May 30, 2024
- Takeda Files 2-Dose Vial Version of Novavax COVID Vaccine
April 15, 2024
- Japan Ends Supply of Takeda/Novavax’s COVID Jab, 7.14 Million Doses Discarded
December 26, 2023
BUSINESS
- Pfizer to Drop Avastin, Herceptin Biosimilars in Japan, Halving Portfolio
October 14, 2026
- Asahi Kasei’s Pritelivir Scores US Approval for HSV Infections
October 14, 2026
- Nitto Medic Recalls Heparinoid Lotion over Nitrosamine Impurity
October 14, 2026
- Moderna Rolls Out XFG-Updated Pediatric Spikevax in Japan
October 14, 2026
- Taiho to Take Over Haiyitan Marketing Authorization from Haihe
October 14, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…